{"id":935480,"date":"2026-02-10T08:32:03","date_gmt":"2026-02-10T13:32:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis\/"},"modified":"2026-02-10T08:32:03","modified_gmt":"2026-02-10T13:32:03","slug":"evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis\/","title":{"rendered":"Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis"},"content":{"rendered":"

<\/p>\n

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis<\/b><\/p>\n

\n– Trial met primary efficacy endpoint at week 12<\/i><\/p>\n

\n– EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo<\/i><\/p>\n

\n– 33% placebo-adjusted improvement in EASI at week 12<\/i><\/p>\n

\n– 23% of EVO301 patients achieved IGA 0\/1 at week 12<\/i><\/p>\n

\n– Company to hold conference call and webcast at 8:30 a.m. ET today<\/i><\/p>\n

PALO ALTO, Calif. & NEW YORK–(BUSINESS WIRE<\/a>)–
\nEvommune, Inc. (NYSE: EVMN) (the \u201cCompany\u201d or \u201cEvommune\u201d), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domain, achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis (AD). The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg\/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.<\/p>\n

\n\u201cThese data underscore that impacting pathways beyond only Th2 biology can meaningfully contribute to AD disease activity. EVO301\u2019s ability to target the novel IL-18 mechanism and show clinically relevant treatment activity, without side effects, could offer real benefit for patients in such a heterogeneous disease,\u201d said Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai. \u201cThere is an urgent need for new treatment options for the growing number of patients suffering from AD. With rapid onset and durable responses, as evidenced by meeting the primary endpoint at weeks 4, 8 and 12 after only two doses, this trial supports the potential of EVO301 to become a front-line biologic treatment in AD, if approved.\u201d<\/p>\n

\n\u201cThis is a big milestone for Evommune and we are pleased to report unequivocally positive data that validate IL-18 inhibition and show significant activity of EVO301 in moderate-to-severe AD patients. These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes,” said Luis Pe\u00f1a, President and Chief Executive Officer at Evommune. \u201cWith multiple programs now having positive Phase 2 data, we are poised to grow into a significant company in the immunology space,\u201d added Mr. Pe\u00f1a.<\/p>\n

Key data highlights include:<\/b><\/p>\n